Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial ResultsPRNewsWire • 02/04/21
Alkermes Announces Strategic Value Enhancement Plan and Continued Board RefreshmentPRNewsWire • 12/10/20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records ReviewPRNewsWire • 11/17/20
Alkermes plc (ALKS) CEO Richard Pops on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/01/20
Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ETPRNewsWire • 10/29/20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial ExpectationsPRNewsWire • 10/29/20
Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial ResultsPRNewsWire • 10/22/20
Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/21/20
Alkermes Nears FDA Ruling For Its Bipolar Treatment With Key Endorsement; ALKS Stock JumpsInvestors Business Daily • 10/12/20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I DisorderPRNewsWire • 10/09/20
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831PRNewsWire • 10/07/20
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual CongressPRNewsWire • 09/18/20